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Although surgery offers the only reasonable expectation of cure
for colorectal cancer, approximately 45% of all patients will go on
to develop metastatic disease. The use of adjuvant chemotherapy
(Moertel et al, 1995) and immunotherapy (Riethmuller et al, 1998)
has been shown to provide survival benefit in node-positive
disease. However, a considerable proportion of patients with node-
negative disease will develop distant metastases (Olson et al,
1980) and adjuvant treatment is not routinely administered to this
group of patients (Moertel et al, 1990). Although the pathological
stage of disease, as defined by the Dukes’ staging system and the
depth of tumour infiltration (AJCC/UICC), can discriminate
patients and yield information with prognostic value, its ability to
predict the outcome of patients with intermediate stage of disease
is poor. Patients with Dukes’ stage B or C tumours that are prone,
for whatever reason, to early disease recurrence would be likely to
benefit from early identification and adjuvant therapy. 
Tumour angiogenesis is essential for solid tumour growth, and
facilitates tumour invasion and the dissemination of metastases
(Folkman, 1990; Ellis and Fidler, 1996). Vascular endothelial
growth factor (VEGF) is one of the most potent angiogenic
proteins known. Our earlier work has shown that serum VEGF
levels are raised in colorectal cancer patients (n = 108) prior to
surgical resections when compared with normal controls (n = 136).
ANOVA demonstrated a significant difference between the
Dukes’ stages (P = 0.007), T stages (P = 0.001) and UICC stages
(P = 0.001). In metastatic and node-positive disease, pre-operative
serum VEGF was elevated compared with metastatic-free 
(P = 0.03), node-negative disease (P = 0.008) and controls 
(P < 0.0005) (Kumar et al, 1998). In addition, in a series of 67
patients who had undergone curative resections for colorectal
cancer, the VEGF concentrations fell post-surgery (P < 0.0005) to
levels comparable with the normal population. There was no fall in
patients (n = 15) who had undergone palliative resections (P =
0.32) or in patients (n = 12) who had undergone resections for
benign disease (P = 0.28) (Kumar et al, 1997). These data suggest
that serum VEGF could be a potential tumour marker in colorectal
cancer. The aim of this study was to assess the clinical usefulness
of pre-operative serum VEGF as a predictor of outcome in patients
who had undergone curative resections for colorectal cancer. 
PATIENTS AND METHODS 
Study population 
This is a prospective sequential cohort study in which 81 patients
with primary colorectal cancer were examined. None of these
patients had received blood transfusion, radiotherapy or
chemotherapy prior to the study. All of these patients had under-
gone curative resection for colorectal cancer; 17 Dukes’ A, 36
Dukes’ B and 28 Dukes’ C disease. All patients underwent stan-
dard radiological staging using either CT or MR abdominal and
liver scanning. Scans were performed either pre-operatively or
within 30 days of surgery in all cases. A single consultant patholo-
gist staged all tumour samples according to TNM, UICC, JASS
and Dukes’ classification. 3 out of 36 patients with Dukes’ B
disease and 16 out of 28 patients with Dukes’ C disease received
adjuvant chemotherapy after surgery. The clinicians were unaware
of the preoperative VEGF levels during the selection of patients
for adjuvant chemotherapy, which was based on standard inter-
national guidelines. The local research ethics committee granted
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Storage of serum 
7 ml of blood was collected pre-operatively. The serum was sepa-
rated after 30 minutes of coagulation and immediately stored at 
–80˚C until immunoassay. 
VEGF assay 
Serums were assayed for VEGF by quantitative sandwich ELISA
(R&D Systems Europe, Oxford, UK). This assay will detect both
soluble forms of VEGF (121 & 165). All of the serum samples and
standards were assayed in duplicate. The minimum detectable
level of VEGF was 9 pg ml–1. In this study, 64 out of 81 patients
also had their pre-operative carcino-embryonic antigen (CEA)
levels determined. 
Follow-up programme after curative resection for
colorectal cancer patients 
All patients were included in a 5-year intensive radiological
follow-up surveillance programme: rectal cancers were staged and
followed-up with pelvic and liver MRI scans; colon cancer was
staged and followed-up with liver CT scans. Our previous experi-
ence has shown no difference between CT and MRI scans in the
detection of metastases and the protocol required patients to
continue within a single imaging modality. The relevant scans
were conducted at 3-monthly intervals for the initial 2 years and
thereafter 6-monthly for the remaining 3 years. Patients also were
subjected to routine surveillance colonoscopy or barium enema
at yearly intervals. All patients complied with one of these two
protocols, and only if they developed metastases, or died, were
alternative courses of action taken. 
Statistical analysis 
Analysis of differences in VEGF levels between the two groups 
of various prognostic factors was performed with Mann-Whitney
U test. The optimal cut-off level of pre-operative serum VEGF
was determined by an analytical method as described by 
Miller and Siegmund (1982). The influence of various clinico-
pathological prognostic factors including the delivery of adjuvant
chemotherapy on the time to development of metastases was
assessed by univariate and multivariate analysis. Initially,
univariate analysis was performed with Cox proportional hazard
model to determine the factors related to the time to development
of metastases. This was followed by forward stepwise multivariate
Cox proportional hazard model to determine if a combination of
prognostic factors provided a better estimate of the relative risk of
time to development of metastases than any single variable. In the
analysis of survival, curves for the disease-free survival and
disease-specific survival were established by the Kaplan–Meier
method and compared with the log-rank test. This also provides
Kaplan–Meier product limit estimates of the survivor and cumula-
tive hazard functions. The standard error estimates are based on
Greenwood’s formula. The confidence interval for survival uses
an asymptotic maximum likelihood solution by transformation as
recommended by Kalbfleisch and Prentice (1980). Cox’s regres-
sion model was also used to examine the combinations of
prognostic factors in the multivariate analysis of disease specific
survival. All P values are two-tailed. 
RESULTS 
Patient outcome 
The median follow-up term for the patients without cancer death
was 27 months (range 21–37). 25 patients developed distant
metastases after curative resection for colorectal cancer. Among
the 25 patients who developed distant metastases, 1 was staged
Dukes’ A, 11 Dukes’ B and 13 Dukes’ C. Peritoneal metastases
occurred in 11 patients, and haematogeneous metastases occurred
in 18 patients (13 liver metastases, 4 lung metastases and 1 bone
metastases). 12 patients died from metastases. The cumulative
metastases-free survival and cumulative disease-specific survival
at 21 months of follow-up was 71% (95% CI 60–80; SE 5.2%) and
88% (95% CI 79–94; SE 3.7%), respectively. 
Association of the pre-operative serum VEGF with
patient profile, and clinicopathological prognostic
factors 
No significant association was observed between pre-operative
serum VEGF and age, gender, adjuvant chemotherapy, tumour
site, tumour size, venous invasion or tumour differentiation.
However, the level of serum VEGF was significantly associated
with the following pathological staging; JASS staging, P = 0.003;
UICC staging, P = 0.0038 and T stage, P = 0.0036, but not nodal
status (Table 1). 
Association of the clinico-pathological prognostic
factors with the time to metastases 
The pre-operative serum VEGF levels were significantly higher in
patients developing metastases than those who did not (713 pg
ml–1 vs. 314 pg ml–1, P < 0.0001, 95% CI 189–438, Mann-Whitney
U test). The prevalence of development of metastases increased
as the serum VEGF increased with maximum prevalence at
600–800 pg ml–1. The optimal cut-off level of pre-operative serum
VEGF was determined at 575 pg ml–1, for which the Chi-square
value of the Cox’s regression was maximal (Miller and Siegmund,
1982). 
The specificity and positive predictive value of serum VEGF at
575 pg ml–1 in predicting the development of metastases in
comparison with the nodal status and CEA are shown in Table 2.
Using the cut-off level of 575 pg ml–1, serum VEGF could predict
the development of metastases with positive predictive value of
73%, negative predictive value of 85%, sensitivity of 64% and
specificity of 89%. Although CEA and nodal status do have some
predictive capability, serum VEGF is by far the best predictor of
outcome, specifically in terms of positive predictive value. 
In comparison with the nodal status, patients with pre-operative
serum VEGF levels higher than 575 pg ml–1 have a much higher
odds ratio and relative risk (Table 3). The odds of development of
metastases for patients with pre-operative serum VEGF higher
than 575 pg ml–1 is 14.8 times that of patients with pre-operative
serum VEGF levels lower than 575 pg ml–1. On the other hand, the
relative risks for the development of metastases for patients with
VEGF higher than 575 pg ml–1 is 4.8 when compared with those
having VEGF lower than 575 pg ml–1. 
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Table 1 Association between preoperative serum VEGF and the clinico-pathological parameters 
Parameter Patient No. Preoperative serum VEGF (pg ml–1) 
Median IQR P value 
Gender 
Male 34 369 (224, 528) NS 
Female 47 364 (193, 721) 
Age 
<65 30 369 (243, 568) NS 
≥ 65 51 364 (192, 727)
Adjuvant chemotherapy 
Yes 19 371 (298, 540) NS 
No 62 361 (214, 697) 
Tumour location 
Colon 55 383 (291, 692) NS 
Rectum 26 296 (168, 549) 
Tumour size 
<5 cm 65 364 (207, 548) NS 
≥ 5 cm 16 547 (327, 758) 
Tumour differentiation 
Well, mucinous 14 486 (371, 759) NS 
Moderately, poorly 67 331 (198, 570) 
Vascular invasion 
Yes 6 565 (291, 768) NS 
No 75 364 (198, 631) 
JASS staging 
J1, J2 44 305 (170, 474) 0.003 
J3, J4 37 522 (320, 746) 
Depth of infiltration 
T1, T2 21 291 (166, 367) 0.0036 
T3, T4 60 425 (280, 734) 
UICC stages 
I 19 250 (164, 364) 0.0038 
II, III 62 416 (290, 729) 
Lymph node metastases 
Negative 53 331 (182, 590) 0.07 
Positive 28 438 (317, 716) 
Distant metastases 
Negative 56 320 (182, 449) <0.0001 
Positive  25 713 (400, 795) 
Peritoneal metastases 
Negative 70 338 (193, 542) 0.0005 
Positive 11 736 (524, 772) 
Haematogenous metastases 
Negative 63 331 (192, 540) 0.0033 
Positive 18 635 (357, 830) 
Liver metastases 
Negative 68 352 (204, 549) 0.0219 
Positive 13 590 (339, 877) 
Table 2 Validity of VEGF at 575 pg ml–1 in predicting the development of metastases 
Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
CEA ≥ 5 ng ml–1 48 63 38 71 
Node-positive 52 73 46 77 
VEGF ≥ 575 pg ml–1 64 89 73 85 
PPV = Positive predictive value; NPV = Negative predictive value. Multivariate analysis of the time to metastases with Cox propor-
tional hazard model was used to determine which clinicopatho-
logical prognostic variables provided an estimate of the relative
risk for development of metastases. Using univariate analysis,
serum VEGF and standard pathological prognostic factors (tumour
size, venous invasion, JASS score, T classes, Dukes’ stages and
nodal status) all gave a significant estimate of relative risk of
development of metastases (Table 4). In contrast, a single, pre-
operative measurement of CEA (CEA ≥ 5 ng ml–1) in 64 patients
was not associated with the development of metastases. However,
using forward stepwise multivariate Cox regression analysis, of all
the variables included in the univariate analysis except serum
CEA, serum VEGF was the most important prognostic factor in
predicting the time to metastases (P < 0.00001; hazard ratio, 6.55;
95% CI, 2.73–15.68). The other independent prognostic factors
were adjuvant chemotherapy (P = 0.0382; hazard ratio, 3.53; 95%
CI, 1.07–11.65) and nodal status (P = 0.0006; hazard ratio, 4.65;
95% CI, 1.93–11.24): Table 5. In summary, the dichotomy of
VEGF levels is more powerful in predicting the time to metastases
than nodal status and will give additional predictive information 
to that available from nodal status and Dukes’ staging (Figure 1).
Although Dukes’ staging is statistically significant in the uni-
variate analysis, it is not a significant independent prognostic
factor in the final model. 
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Table 3 Prediction of development of metastases: VEGF versus nodal
status 
VEGF < 575 pg ml–1 VEGF ≥ 575 pg ml–1
M0 50 6 
M+ 9 16 
Odds ratio = 14.8, Relative risk = 4.8 
Node-negative Node-positive 
M0 41 15 
M+ 12 13 
Odds ratio = 3, Relative risk = 2 
Dukes’ B,  Dukes’ B, 
VEGF ≥ 575 pg ml–1 VEGF < 575 pg ml–1
M0 20 5 
M+ 5 6 
Odds ratio = 4.8, Relative risk = 2.7. 
M0 = Metastases free; M+ = Development of metastases.
Table 4 Univariate analysis of clinico-pathological factors in relation to time to development of metastases
determined by Cox regression for patients undergoing curative resections for colorectal cancer 
Prognostic factors Hazard ratio 95% CI P value 
Age (≥ 65/<65) 1.37 0.59–3.18 0.4601 
Gender (female/male) 1.03 0.47–2.28 0.9349 
Size (≥ 5/<5) 2.62 1.16–5.94 0.0209 
Differentiation (poor/well) 0.59 0.23–1.47 0.2538 
Location (rectum/colon) 0.40 0.14–1.16 0.0928 
Venous invasion (positive/negative) 3.57 1.22–10.43 0.0200 
JASS stage (III, IV/I, II) 2.96 1.28–6.87 0.0114 
Depth of infiltration (T III, IV/I, II) 4.32 1.02–18.33 0.0472 
UICC stage (III, IV/I, II) 3.65 0.86–15.48 0.0792 
Nodal status (positive/negative) 2.52 1.15–5.53 0.0212 
Dukes’ stages (overall) 0.0478 
Dukes’ C/Dukes’A 9.58 1.25–73.25 0.0295 
Dukes’ B/Dukes’ A 5.10 0.66–39.47 0.1190 
CEA (≥ 5 ng ml–1 / <5 ng ml–1): subset of 64 patients 1.34 0.57–3.17 0.4996 
Adjuvant chemotherapy (no/yes) 1.85 0.63–5.38 0.2619 
VEGF (≥ 575 pg ml–1 / <575 pg ml–1) 7.14 3.11–16.38 <0.00001 
Table 5 Multivariate analysis of various clinico-pathological factors in relation
to time to development of metastases determined by forward stepwise Cox
regression (final model) for patients undergoing curative resections for
colorectal cancer 
Prognostic factors Hazard ratio 95% CI P value
Adjuvant chemotherapy 3.53 1.07–11.65 0.0382 
(no/yes)
Nodal status 4.65 1.93–11.24 0.0006 
(positive/negative)
VEGF 6.55 2.73–15.68 <0.00001 
(≥ 575 pg ml–1 / <575 pg ml–1) Patients in this study were also subdivided into two groups
according to their nodal status, and were investigated for any
possible relationship between pre-operative serum VEGF and
outcome. 12 of the 25 patients who developed metastases were
staged as node-negative disease. 6 of these 12 patients had their
pre-operative serum VEGF levels above 575 pg ml–1 and therefore
had a relative risk of at least 68% for developing metastases. None
of these patients received adjuvant chemotherapy because of their
nodal status as determined by pathological examination. In the
Dukes’ B disease group, patients with pre-operative serum VEGF
higher than 575 pg ml–1 have a much greater odds ratio and relative
risk of development of metastases (odds ratio = 4.8, relative risk =
2.7) than the patients with node-positive disease alone. Within the
node-negative group, the disease-free survival is greater in patients
with VEGF levels lower than 575 pg ml–1, than those with VEGF
higher than 575 pg ml–1 (P = 0.0013, log-rank test). Similarly,
measurement of VEGF levels can further split the disease-free
survival curve of Dukes’ B patients, and provides additional
Pre-op VEGF as a prognostic marker 1429
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Figure 1 Disease-free survival curves for colorectal cancer patients
according to nodal status, Dukes’ stage and pre-operative serum VEGF level.
Kaplan Meier disease-free survival curves show that patients with: node-
positive disease have a worse survival than those with node-negative
disease (A); Log rank test, P = 0.0164; Dukes’ stage C have a worse survival
than Dukes’ stage B (B); Log rank test P = 0.0197; pre-operative serum
VEGF levels ≥ 575 pg ml–1 have a worse survival than those patients with
levels below 575 pg ml–1 (C), Log rank test P < 0.00001.
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Figure 2 Disease-free survival curves for patients with Dukes’ B and 
Dukes’ C disease according to VEGF levels. Kaplan Meier disease-free
survival curves show that patients with Dukes’ B or Dukes’ C disease and
pre-operative serum VEGF levels ≥ 575 pg ml–1 have a worse survival (A and
B respectively); Log rank test, P < 0.00001 in both cases.
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(B)information in predicting the development of metastases (Figure 2A,
P < 0.00001, log-rank test). 
In the node-positive group, all the patients who did not go
on to develop metastases had pre-operative VEGF levels below
575 pg ml–1. On the other hand, 9 out of 13 patients (69%) with
node-positive disease who went on to develop metastases had their
VEGF levels above 575 pg ml–1. Thus, VEGF at 575 pg ml–1 can
correctly predict the disease-free survival within the node-positive
disease group (Figure 2B, P < 0.00001, log-rank test). Further-
more, patients with serum VEGF higher than 575 pg ml–1
were shown to have a poorer disease-specific survival rate 
(P < 0.00001, log-rank test). 
Patients with Dukes’ C have a poorer disease-specific survival
than those patients with Dukes’ B, while none of the patients with
Dukes’ A died from cancer (P = 0.0044, log-rank test). In addition,
using the cut-off level of 575 pg ml–1, pre-operative serum VEGF
was also the most important independent prognostic factor in
predicting the disease-specific survival using multivariate forward
stepwise Cox regression analysis in this data set (VEGF, 
P = 0.0004; hazard ratio = 19.42; 95% CI 3.76–100.33, nodal
status,  P = 0.0445; hazard ratio = 4.41; 95% CI 1.04–18.72,
tumour size, P = 0.0460; hazard ratio = 3.78; 95% CI 1.02–13.98). 
DISCUSSION 
Our studies showed a significant correlation between the pre-
operative level of serum VEGF and the probability of survival and
of recurrence-free survival in colorectal cancer patients after
curative resection. Patients with distant metastases at the time of
surgery were excluded so that the evaluation of serum VEGF as a
prognostic marker would be more specific and more appropriate
for assessment of the clinical usefulness of this potential tumour
marker. Previous studies have shown that VEGF expression is
associated with the stage of progression and metastases in
colorectal cancer and may play a predictive role in the prognosis
of the disease (Takahashi et al, 1997; Ishigami et al, 1998). Salven
and colleagues have shown that high pre-treatment serum VEGF
predicts poor response to chemotherapy and poor survival in
small-cell lung cancer (Salven et al, 1998). A similar study in
patients with non-Hodgkin’s lymphoma also demonstrated that
patients with higher than median serum VEGF pre-treatment have
a poorer survival rate than those patients with serum levels below
the median value (Salven et al, 1997). Our current study on
colorectal cancer patients undergoing curative resection has
demonstrated that pre-operative serum VEGF is the most impor-
tant independent prognostic factor for determining the future
development of metastases, disease-free survival and disease-
specific survival. The higher the level of serum VEGF prior to
curative resection, the greater the risk of developing distant meta-
stases in the future. 
Our studies have indicated that angiogenesis plays a vital role in
the development of metastases (Ellis and Fidler, 1996; Folkman
and Shing, 1992). The higher levels of serum VEGF in those
patients that went on to develop metastases, despite curative
resection, might reflect the increased tumour load and hence an
increased metastatic potential for purely stochastic reasons. In
addition, it has been shown that increased serum VEGF levels
were significantly correlated with high microvessel density and
VEGF expression in primary breast tumour tissue (Yamamoto et
al, 1996). Therefore, it is likely that the high levels of serum
VEGF reflect the degree of angiogenesis at the tumour site, which
facilitates the dissemination of cancer cells into the circulation
(Folkman, 1994). It is also probable that the relatively high level
of serum VEGF systemically may provide the required environ-
ment for establishment of adequate angiogenesis at distant
metastatic sites. The significant association between the pre-
operative VEGF levels and the development of haematogenous
and peritoneal metastases reported here supports this hypothesis.
On the contrary, the lack of association between the pre-operative
serum VEGF levels and the lymph node metastases suggests that
VEGF may not facilitate metastatic spread via the lymphatic
vessels. However, Yonemura et al (1999) have found a strong
correlation between VEGF-C tissue expression status and the
grade of lymph node metastases in gastric cancer. This finding
suggests that VEGF-C rather than VEGF may be important in the
development of lymphatic spread. 
Of all the patients presented with colorectal cancer, approxi-
mately 70% are resectable with curative intent, and 45% are
indeed cured by primary resection. However, the cancer in the
remaining 25% of curative resections recurs, most commonly
during the first two years after resection (August et al, 1984). The
majority of mortality from colorectal cancer is attributed to the
development of metastases. The prognosis of metastatic cancer is
influenced by a variety of clinico-pathological features present at
the initial diagnosis (Williams et al, 1988; Deans et al, 1992;
Hermanek et al, 1995). The most widely accepted prognostic
factor in colorectal cancer is the presence of lymph node meta-
stases (Cohen et al, 1991), which is pivotal for the decisions
regarding adjuvant chemotherapy. However, a considerable
proportion of patients with node-negative disease goes on to
develop metastases, 23% in this study. Recently, IMPACT B2
investigators have concluded that there is no good evidence to
support the routine use of adjuvant fluorouracil and folinic acid in
B2 (T3 and T4, N0 M0) colon cancer. Instead, they have indicated
the need for more pertinent biological markers to identify a
subgroup of patients at high risk of disease recurrence (IMPACT
B2 investigators, 1999). The data from our study has shown that
pre-operative serum VEGF levels can provide additional informa-
tion to Dukes’ staging in the prediction of a sub-group of patients
who are most likely to develop aggressive metastases during the
first 2 years following surgical resection; the period of time when
patients are most vulnerable to disease recurrence (Pestana et al,
1964; Polk and Spratt, 1971; August et al, 1984). This study
indicates that patients with high pre-operative serum VEGF levels
were exposed to high risk of early aggressive metastases. Pre-
operative selection of this sub-group of patients for neo-adjuvant
or immediate delivery of aggressive adjuvant chemotherapy after
surgery might prolong the survival of these patients. In addition,
pre-operative identification of patients with Dukes’ B tumours
with a high risk of metastases by a single measurement of serum
VEGF is highly likely to improve the survival of this group of
colorectal cancer patients by the use of adjuvant therapy following
surgery. Furthermore, identification of such patients can facilitate
the surgical decision regarding local versus radical resection and
neoadjuvant radio-chemotherapy, in patients with rectal cancer.
On the other hand, pre-operative serum VEGF is also useful for
selecting patients with node-positive disease that would not
benefit from aggressive adjuvant treatments after surgery. These
data suggest that serum VEGF can stage Dukes’ B and C disease
further, and may become the tumour marker of choice to select
patients for adjuvant therapy. 
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